27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Novartis (NYSE:NVS) decreased 1.6% in pre-market trading after the company reported Q3 results.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Quarterly Results
Earnings per share rose 7.80% year over year to $1.52, which beat the estimate of $1.45.
Revenue of $12,259,000,000 rose by 0.71% year over year, which missed the estimate of $12,530,000,000.
Outlook
Novartis hasn't issued any earnings guidance for the time being.
Novartis hasn't issued any revenue guidance for the time being.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Details Of The Call
Date: Oct 27, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3soac2di
Price Action
Company's 52-week high was at $99.84
52-week low: $69.18
Price action over last quarter: down 4.24%
Company Profile
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.